2. Cost effectively maximizing oral bioavailability of existing and emerging drug technologies through better drug delivery design. Tamarisk’s Value Statement to the Pharmaceutical Industry

3. MxBA TM Oral Delivery System Recent Advances  Refinements to delivery particle technology  Demonstrated the MxBA TM platform supports effective delivery of proteins/peptides  Released independent pre-clinical study results showing unparalleled relative bioavailability of oral to sub-cutaneous insulin administration  Expanded IP portfolio

4.  Oral administration is generally viewed by most clinicians as the superior delivery method as it lowers many of the barriers for patient compliance.  Tamarisk’s MxBA TM platform is an oral delivery system that microencapsulates therapeutic agents within a novel gastric protective alginate matrix enhanced to maximize absorption.  Tamarisk’s focus and successes have been with optimizing difficult to deliver oral biologics.  This novel technology is protected by issued and pending patents, trade secrets and oral delivery know-how. MxBA TM Oral Delivery System Enhanced Oral Delivery

5. Technology Highlights

6. Range of Therapeutic Payloads Biologics, including proteins and peptides Small molecules Hydrophilic and hydrophobic molecules Increased Oral Bioavailability by: Minimizing gastric disintegration of therapeutic payload Targeted release Capitalizing on features of the local GI environment for assisted absorption Technology Highlights

7. Alginate Matrix

8. Active Targeting Motif

9. Particle

10. Note: Studies conducted by Charles River Laboratories with Rattus Norvegicus in a Single Dose Study. Insulin Insulin Subcutaneous Controls (5 U/kg) Tamarisk MxBA Encapsulated Insulin (50 U/kg) Relative Bioavailability AUC 0-x ng*h/mL86.8464.554% Pre-Clinical Results Resveratrol Mean unencapsulated Resveratrol (20 mg/ml dose) Tamarisk MxBA encapsulated Resveratrol (20 mg/ml dose) Change AUC 0-t ng*h/mL82.83123.8X increase C max ng*h/mL82.44986.0X increase t max h1.50.51 hr faster MxBA TM Oral Delivery System

11. Tamarisk currently has availability to expand its partner portfolio for its MxBA TM Delivery System. If your company realizes the enormous value of orally delivered biologics, it's time to take action now to ensure your place in this future commanding marketplace. Reach out to Tamarisk now! Partnering Opportunity

12. Tamarisk’s MxBA TM Delivery System opens new avenues of development for new drug technologies in the 21 st century. Let one of Tamarisk’s Application Specialist custom design an oral delivery experience for you that is second to none. Proof of concept test samples can be readily manufactured with your active No additional complex synthesis High encapsulation efficiency Biologic or small molecule capable Hydrophobic or hydrophilic APIs Lab-scale operation ready to go Analytical testing and method development services available Next Steps Visit us online at www.tamarisktechgroup.com

13. Tamarisk Technologies Group © 2016 All Rights Reserved. No part of this presentation may be copied, modified, printed, or presented without the author’s permission. #NoMoreNeedles

14. Visit us online at www.tamarisktechgroup.com